Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease.
Lam
Gordon K
GK
Hummers
Laura K
LK
Woods
Adrianne
A
Wigley
Fredrick M
FM
D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005260:Female; D006304:Health Status; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012189:Retrospective Studies; D045743:Scleroderma, Diffuse / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D045745:Scleroderma, Limited / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D012720:Severity of Illness Index; D013585:Synovitis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept